Rights and permissions
About this article
Cite this article
Herd immunity confers added cost benefit for pneumococcal vax. Pharmacoecon. Outcomes News 474, 10 (2005). https://doi.org/10.2165/00151234-200504740-00018
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504740-00018